# Phase 3 cancer trials recruiting: 804 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 804 trials in phase 3 for cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 cancer trials: 804 rows for $40.20, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 22 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 804
- Recruiting or not yet: 804
- Read on: November 19, 2026

## Trials

The 25 newest of 804, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07947121 | A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer... | GlaxoSmithKline | Phase 3 | Not yet recruiting | Lung Neoplasm | 700 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07947121) |
| November 12, 2026 | NCT07931261 | \[18F\]FET PET for Differentiating Tumor Progression vs Treatment-Related Changes in Brain Metastases | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 3 | Not yet recruiting | Brain Metastasis, Radiation Necrosis, Pseudoprogression, Tumor Progression | 381 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931261) |
| November 9, 2026 | NCT07926048 | A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926048) |
| November 4, 2026 | NCT07916844 | Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer | Sponsor not shown (see the record) | Phase 3 | Not yet recruiting | Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916844) |
| November 4, 2026 | NCT07915739 | Internal Mammary Node Irradiation After Neoadjuvant Systemic Therapy for Breast Cancer | Mahidol University | Phase 3 | Not yet recruiting | Breast Neoplasms | 1,760 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915739) |
| November 3, 2026 | NCT07914101 | Sequential Chemotherapy Followed by Ultrahypofractionated Radiotherapy for Muscle-Invasive Bladder Cancer | Assiut University | Phase 3 | Not yet recruiting | Bladder Cancer, TURBT, Radiotherapy | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914101) |
| November 3, 2026 | NCT07913360 | GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer | Genfleet Therapeutics (Shanghai) Inc. | Phase 3 | Not yet recruiting | Colorectal Cancer | 368 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913360) |
| October 30, 2026 | NCT07906717 | A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer | Janssen Research & Development, LLC | Phase 3 | Recruiting | Prostatic Neoplasms | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906717) |
| October 28, 2026 | NCT07900061 | Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Rectal Cancer | Sir Run Run Shaw Hospital | Phase 3 | Not yet recruiting | Rectal Cancer | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900061) |
| October 27, 2026 | NCT07898943 | Evaluation of the Effect of Antibiotic Prophylaxis During Lumpectomy for Breast Cancer: Prospective Randomised Double-blind Noninferiority... | University Hospital, Clermont-Ferrand | Phase 3 | Not yet recruiting | Breast Cancer, Breast Surgery, Surgical Site Infection (SSI), Surgical Site Infection Prevention | 1,600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898943) |
| October 27, 2026 | NCT07898033 | 1 Year Recurrence After Modified en Bloc Resection (ERBT) vs Transurethral Resection (TURBT) for Large Bladder Tumors | Sponsor not shown (see the record) | Phase 3 | Recruiting | NMIBC, TCC | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898033) |
| October 26, 2026 | NCT07894328 | A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | Not yet recruiting | Breast Cancer | 1,050 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894328) |
| October 23, 2026 | NCT07892274 | Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 | Not yet recruiting | Metastatic Breast Cancer (MBC), HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer | 226 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892274) |
| October 22, 2026 | NCT07890597 | A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative... | Pfizer | Phase 3 | Not yet recruiting | Early Breast Cancer, Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) | 3,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890597) |
| October 22, 2026 | NCT07888140 | Modular Robot-Assisted Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer | Ruijin Hospital | Phase 3 | Recruiting | Esophageal Cancer | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888140) |
| October 21, 2026 | NCT07885384 | Fruquintinib Combined With Capecitabine as Adjuvant Extended Therapy After R0 Resection and Perioperative Chemotherapy in Patients With... | West China Hospital | Phase 3 | Not yet recruiting | Colorectal Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885384) |
| October 20, 2026 | NCT07883005 | SALI-10 Probiotic to Reduce Osteoradionecrosis and Dental Toxicity Following Radiation Therapy for Head and Neck Cancer | University Health Network, Toronto | Phase 3 | Not yet recruiting | Head and Neck Cancer | 288 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883005) |
| October 19, 2026 | NCT07879911 | A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or... | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Not yet recruiting | Triple Negative Breast Cancer | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07879911) |
| October 16, 2026 | NCT07878156 | Dexmedetomidine Use for Greater Occipital Nerve Block in Pediatric Posterior Fossa Tumor Surgery. | Children's Cancer Hospital Egypt 57357 | Phase 3 | Recruiting | Posterior Fossa Tumor | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07878156) |
| October 16, 2026 | NCT07877597 | Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally... | Fudan University | Phase 3 | Not yet recruiting | Locally Advanced Colon Cancer, pMMR | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877597) |
| October 13, 2026 | NCT07869836 | BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial... | SystImmune Inc. | Phase 3 | Recruiting | Urothelial Cancer, Metastatic Urothelial Cancer, Bladder Cancer, Bladder Cancer (BC), Bladder (Urothelial, Transitional... | 520 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869836) |
| October 9, 2026 | NCT07867002 | Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer | UNC Lineberger Comprehensive Cancer Center | Phase 3 | Recruiting | Endometrial Adenocarcinoma, Metastatic Endometrial Cancer, Endometrial Cancer, Recurrent Endometrial Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867002) |
| October 6, 2026 | NCT07860450 | Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent... | GlaxoSmithKline | Phase 3 | Not yet recruiting | Endometrial Carcinoma, Neoplasms, Endometrial | 378 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07860450) |
| October 5, 2026 | NCT07859215 | Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line... | Genmab | Phase 3 | Not yet recruiting | Ovarian Cancer | 602 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859215) |
| October 1, 2026 | NCT07853209 | A Phase 3 Study of \[177Lu\]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer | FutureChem | Phase 3 | Recruiting | Prostate Cancer, mCRPC | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07853209) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Fudan University | 48 |
| Sun Yat-sen University | 30 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 19 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 15 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 13 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 11 |
| NRG Oncology | 10 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 10 |
| UNICANCER | 8 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 8 |
| Gustave Roussy, Cancer Campus, Grand Paris | 8 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 7 |
| SWOG Cancer Research Network | 7 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 7 |
| Canadian Cancer Trials Group | 7 |
| Ruijin Hospital | 7 |
| Sixth Affiliated Hospital, Sun Yat-sen University | 6 |
| National Cancer Institute (NCI) | 6 |
| [Genmab](https://specstream.ai/data/clinical-trials/company/genmab) | 6 |
| [Daiichi Sankyo](https://specstream.ai/data/clinical-trials/company/daiichi-sankyo) | 6 |
| [Suzhou Suncadia Biopharmaceuticals Co., Ltd.](https://specstream.ai/data/clinical-trials/company/suzhou-suncadia-biopharmaceuticals-co-ltd) | 6 |
| [Revolution Medicines, Inc.](https://specstream.ai/data/clinical-trials/company/revolution-medicines-inc) | 6 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 6 |
| M.D. Anderson Cancer Center | 5 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 5 |

## By country

| Country | Trials |
| --- | --- |
| China | 326 |
| United States | 235 |
| France | 141 |
| Italy | 122 |
| Canada | 120 |
| South Korea | 118 |
| Germany | 116 |
| Spain | 113 |
| Japan | 105 |
| United Kingdom | 103 |
| Australia | 101 |
| Belgium | 91 |
| Poland | 87 |
| Taiwan | 82 |
| Netherlands | 81 |
| Brazil | 80 |
| Argentina | 55 |
| Greece | 53 |
| Czechia | 52 |
| Israel | 52 |
| Turkey (Türkiye) | 49 |
| Sweden | 49 |
| Denmark | 45 |
| Hungary | 42 |
| Austria | 42 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Contract law firms in the United States](https://specstream.ai/data/businesses/contract-law-firms/united-states)
- [Roofing contractors in the United States](https://specstream.ai/data/businesses/roofing-contractors/united-states)
- [Eye care clinics in the United States](https://specstream.ai/data/businesses/eye-care-clinics/united-states)
- [Traffic ticketing law firms in the United States](https://specstream.ai/data/businesses/traffic-ticketing-law-firms/united-states)
- [Hotel bars in the United States](https://specstream.ai/data/businesses/hotel-bars/united-states)
- [Appellate practice law firms in the United States](https://specstream.ai/data/businesses/appellate-practice-law-firms/united-states)
